That maximum is 4.5939 MMED shares for each MDT share. Medtronic’s official indicative calculations have been pinned at the cap since September 22.
The cap is already reducing the value of the offer
As of October 2, Medtronic’s official exchange-offer site showed an indicative calculated MDT value of $86.4156 and an indicative MMED value of $19.5603. Without the cap, those values would produce an exchange ratio of approximately 4.7504 MMED shares for each MDT share.
Instead, the ratio is limited to 4.5939. At the October 2 indicative MMED value, those shares are worth about $89.86 compared with $86.42 of MDT being exchanged. That is an indicative value advantage of roughly 4.0%, rather than the approximately 7.53% additional value available when the full discount can be delivered.
| Date | Indicative Exchange Ratio | Upper Limit in Effect? |
|---|---|---|
| Sept. 16 | 4.5306 | No |
| Sept. 22 | 4.5939 | Yes |
| Oct. 2 | 4.5939 | Yes |
The cap does not have to remain binding through final pricing. A sufficiently favorable move in MDT relative to MMED could push the calculated ratio back below 4.5939. But investors enter the actual averaging period with the maximum having constrained the indicative ratio for nine consecutive trading sessions.
Pricing runs October 5 through October 7
The final exchange ratio will be based on the simple average of the daily volume-weighted average prices of MDT and MMED on October 5, 6 and 7, assuming the offer is not extended. The uncapped ratio is calculated by dividing the average MDT price by 93% of the average MMED price.
Medtronic plans to post updated indicative information after the first two days of the averaging period. The final exchange ratio should be announced after the October 7 pricing period and no later than 9:00 a.m. Eastern on October 8.
The exchange offer is scheduled to expire at midnight at the end of October 9. Shares tendered into the offer generally can be withdrawn until expiration, although individual brokers may impose earlier internal deadlines.
Proration remains a separate risk
Medtronic is offering up to 225,361,295 MiniMed shares through the exchange offer. If investors tender more MDT shares than Medtronic can accept, ordinary tenders will generally be accepted on a pro rata basis.
Qualifying odd lots are exempt from that proration. A shareholder who beneficially owns fewer than 100 MDT shares and validly tenders all of them is not subject to proration if the offer is oversubscribed.
That provision creates a different set of economics for small shareholders. We examine the MiniMed odd-lot exchange offer and the 99-share trade in more detail at Inelegant Investor.
What matters now
The exchange offer still showed a positive spread heading into the pricing period. The relevant number, however, was approximately 4% based on the October 2 indicative values, not the full headline discount.
The next three trading sessions determine whether that spread widens, narrows or allows the calculated exchange ratio to fall back below the cap. Once the October 5–7 VWAPs are known, investors will have the final economics rather than an indicative calculation.
We previously covered Medtronic’s MiniMed separation and subsequent split-off structure. For other announced transactions and distribution dates, see our Upcoming Spinoffs page.